GILEAD SCIENCES, INC. Payments to Acquire Debt Securities, Available-for-sale
GILEAD SCIENCES, INC. (GILD) reported Payments to Acquire Debt Securities, Available-for-sale of $551.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $26.00M, a 98.70% decline year-over-year.
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $525.00M.
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $1.38B.
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $270.00M.
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $3.94B, a 1514.34% increase from fiscal 2024.
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $244.00M, a 87.36% decline from fiscal 2023.
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $1.93B, a 9.04% increase from fiscal 2022.
- GILEAD SCIENCES, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $1.77B, a 49.67% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $551.00M 10-Q · filed 2026-08-06 | $1.93B derived: sum of 3 quarters · filed 2026-08-06 | $2.20B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $525.00M 10-Q · filed 2026-05-07 | $1.91B derived: sum of 2 quarters · filed 2026-05-07 | $2.18B derived: sum of 3 quarters · filed 2026-05-07 | $4.18B derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $1.38B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.65B derived: sum of 2 quarters · filed 2026-02-24 | $3.65B derived: sum of 3 quarters · filed 2026-02-24 | $3.94B 10-K · filed 2026-02-24 |
| 2025-09-30 | $270.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $2.27B derived: sum of 2 quarters · filed 2025-11-07 | $2.56B 10-Q · filed 2025-11-07 | $2.27B derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $2.00B 10-Q · filed 2025-08-07 | $2.29B 10-Q · filed 2026-08-06 | $2.00B derived: sum of 3 quarters · filed 2026-05-07 | $2.00B derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $244.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $244.00M 10-Q · filed 2025-11-07 | $700.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $244.00M 10-Q · filed 2025-08-07 | $700.00M derived: sum of 3 quarters · filed 2026-02-24 | $1.07B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $244.00M 10-Q · filed 2025-05-07 | $700.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.07B derived: sum of 3 quarters · filed 2026-02-24 | $1.65B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $456.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $825.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.40B derived: sum of 3 quarters · filed 2026-02-24 | $1.93B 10-K · filed 2026-02-24 |
| 2023-09-30 | $369.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $947.00M derived: sum of 2 quarters · filed 2024-11-12 | $1.47B 10-Q · filed 2024-11-12 | $1.85B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $578.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.10B 10-Q · filed 2024-08-08 | $1.48B derived: sum of 3 quarters · filed 2025-02-28 | $1.78B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $527.00M 10-Q · filed 2024-05-08 | $899.00M derived: sum of 2 quarters · filed 2025-02-28 | $1.21B derived: sum of 3 quarters · filed 2025-02-28 | $1.68B derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $372.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $680.00M derived: sum of 2 quarters · filed 2025-02-28 | $1.16B derived: sum of 3 quarters · filed 2025-02-28 | $1.77B 10-K · filed 2025-02-28 |
| 2022-09-30 | $308.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $785.00M derived: sum of 2 quarters · filed 2023-11-07 | $1.40B 10-Q · filed 2023-11-07 | $2.02B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-06-30 | $477.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $1.09B 10-Q · filed 2023-08-04 | $1.72B derived: sum of 3 quarters · filed 2024-02-23 | $2.53B derived: sum of 4 quarters · filed 2024-02-23 |
| 2022-03-31 | $613.00M 10-Q · filed 2023-05-03 | $1.24B derived: sum of 2 quarters · filed 2024-02-23 | $2.05B derived: sum of 3 quarters · filed 2024-02-23 | $3.20B derived: sum of 4 quarters · filed 2024-02-23 |
| 2021-12-31 | $626.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $1.44B derived: sum of 2 quarters · filed 2024-02-23 | $2.59B derived: sum of 3 quarters · filed 2024-02-23 | $3.52B 10-K · filed 2024-02-23 |
| 2021-09-30 | $813.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $1.96B derived: sum of 2 quarters · filed 2022-11-02 | $2.89B 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $1.15B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.08B 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $931.00M 10-Q · filed 2022-05-04 | |||
| 2020-09-30 | $3.06B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $6.65B derived: sum of 2 quarters · filed 2021-11-03 | $19.81B 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $3.60B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $16.75B 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $13.16B 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |